Blog

Dublin, OH — February 1, 2024 –

Dublin-based DASI Simulations takes center stage in healthcare innovation, contributing to Dublin’s reputation as a prominent healthcare hub. The company’s flagship product, PrecisionTAVI, utilizes predictive modeling and artificial intelligence (AI) to enhance transcatheter aortic valve replacement (TAVR) procedures. With FDA clearance in May 2023 and recent approval from the Centers for Medicare & Medicaid Services (CMS) for a reimbursement code, PrecisionTAVI aims to revolutionize structural heart care, predicting treatment outcomes and minimizing complications.

Co-founded by Teri Sirset and Dr. Lakshmi Dasi in 2020, DASI Simulations addresses the challenges of surgery planning through personalized AI-powered simulations. PrecisionTAVI allows physicians to visualize device interactions within a patient’s anatomy, facilitating improved decision-making. With CMS’s groundbreaking decision, DASI Simulations anticipates greater accessibility to its innovative technology, making significant strides in reshaping healthcare delivery. As the company expands into other areas of structural heart and beyond, it continues to pioneer advancements that promise better patient outcomes and substantial cost savings in preventable complications.